Sunshine Biopharma (SBFM) is a Canada-based pharmaceutical and nutritional supplement company that is engaged in the research and development of anticancer drugs. The company’s lead product candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin that is being developed to treat various forms of cancer. The company also develops and markets one nutritional supplement product through its wholly-owned Canadian subsidiary, Sunshine Biopharma Canada Inc.
Since the beginning of the year, shares of Sunshine Biopharma have dropped about 48%, underperforming the broader market and its benchmark, the SPDR S&P Biotech ETF (XBI), which has slid about 22% during the same period. However, in the past month, the company's share price rallied more than 100% after it had announced that two of its mRNA molecules were efficient against cancer cells.
